Finally, Merck is a terrific dividend stock that has increased its payouts by 84.7% over the past decade and currently offers ...

Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™ ...

Aug 1 (Reuters) - Merck KGaA (MRCG.DE), opens new tab is seeing a faster-than-expected improvement in its semiconductor materials business and is aiming to accelerate its drug development pipeline, ...

Merck’s MRK stock has risen 30.4% this year so far compared with an increase of 4.3% for the industry. An ongoing recovery from the disruptions related to the pandemic and strong global underlying ...

Merck MRK boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

In November 2025, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for primary ...

Merck announced it has filed a Form 10 registration statement with the United States Securities and Exchange Commission in connection with the intended spinoff of its women’s health, biosimilars and ...